...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Unleashing the Immune System With Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Clinical Review of Adverse Events
【24h】

Unleashing the Immune System With Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Clinical Review of Adverse Events

机译：用非小细胞肺癌检查点抑制剂释放免疫系统：对不良事件的临床审查

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immunotherapy checkpoint inhibitors have dramatically changed our management of metastatic non-small cell lung cancer (NSCLC). Efficacy data have supported immune checkpoint inhibitors as potential first-line options as monotherapy or in combination with chemotherapy. In addition, they are approved as second-line options after a platinum doublet. Their efficacy represents an unprecedented milestone in metastatic NSCLC. In this new age of immunotherapy, health-care professionals are not experienced in the unique side-effect profile that immunotherapy brings to clinical practice. In general, immune checkpoint inhibitors are well tolerated, but fatal adverse events can occur. Therefore, it is imperative that health-care professionals are educated on the monitoring, identification, and management of the immune-related adverse events (irAEs) that can occur with immune checkpoint inhibitors. This article will review the mechanisms of action, incidence, and management of the most common irAEs that occur with the US Food and Drug Administration-approved checkpoint inhibitors in metastatic NSCLC.
机译：免疫治疗检查点抑制剂极大地改变了我们对转移性非小细胞肺癌（NSCLC）的管理。疗效数据支持免疫检查点抑制剂作为潜在的一线选择，如单一疗法或联合化疗。此外，在白金双人床之后，它们被批准为二线选择。它们的疗效代表了转移性NSCLC的一个前所未有的里程碑。在这个免疫治疗的新时代，卫生保健专业人员在免疫治疗给临床实践带来的独特副作用方面缺乏经验。一般来说，免疫检查点抑制剂耐受性良好，但可能发生致命的不良事件。因此，医疗保健专业人员必须接受有关免疫检查点抑制剂可能发生的免疫相关不良事件（IRAE）的监测、识别和管理的教育。本文将回顾美国食品和药物管理局批准的检查点抑制剂在转移性NSCLC中最常见的IRAE的作用机制、发病率和管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号